CS
FDMT icon

Credit Suisse’s 4D Molecular Therapeutics FDMT Stock Holding History

Credit Suisse’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$765K Buy
24,016
+1,690
+8% +$43.1K ﹤0.01% 2425
2023
Q4 		$452K Sell
22,326
-3,418
-13% -$45K ﹤0.01% 2777
2023
Q3 		$328K Sell
25,744
-8,873
-26% -$148K ﹤0.01% 2899
2023
Q2 		$626K Buy
34,617
+21,152
+157% +$389K ﹤0.01% 2664
2023
Q1 		$231K Buy
13,465
+13,464
+1,346,400% +$262K ﹤0.01% 3078
2022
Q4 		$22 Sell
1
-17,547
-100% -$271K ﹤0.01% 3661
2022
Q3 		$141K Buy
17,548
+140
+0.8% +$1.27K ﹤0.01% 3346
2022
Q2 		$122K Sell
17,408
-1,242
-7% -$12.1K ﹤0.01% 3495
2022
Q1 		$282K Buy
18,650
+3,682
+25% +$57.8K ﹤0.01% 3248
2021
Q4 		$329K Buy
14,968
+6,023
+67% +$148K ﹤0.01% 4083
2021
Q3 		$241K Buy
+8,945
New +$255K ﹤0.01% 4165

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's FDMT Position: Q1 2024 in Review

Credit Suisse increased its 4D Molecular Therapeutics (FDMT) stake by 7.6% in Q1 2024, buying an estimated $43.1K and bringing the position to 24,016 shares worth $765K. The position accounts for ﹤0.01% of the portfolio, ranked #2425.

Credit Suisse first reported a position in FDMT in Q3 2021 and has held it in 11 quarters since. 147 funds tracked by Wall St. Rank hold FDMT as of Q1 2024.

  • Credit Suisse held 24,016 shares of 4D Molecular Therapeutics worth $765K as of Q1 2024.
  • Credit Suisse bought 1,690 4D Molecular Therapeutics shares in Q1 2024, an estimated $43.1K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2425 holding.
  • Credit Suisse first reported a position in 4D Molecular Therapeutics in Q3 2021 and has held it in 11 quarters since.
  • 147 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.